Roche reports a strong start in 2019 and raises the outlook for the full-year
Group sales increase 8% at constant exchange rates and 9% in Swiss francs Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta, Hemlibra and Tecentriq Diagnostics Division sales grow 1%, with Molecular Diagnostics as main contributor (Source: Roche Investor Update)
Source: Roche Investor Update - April 17, 2019 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's First Quarter Sales 2019 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2019 prior to the opening of the Swiss Stock Exchange on Wednesday, April 17th, 2019 (Source: Roche Investor Update)
Source: Roche Investor Update - April 11, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.
Roche and Spark Therapeutics, Inc. ( “Spark”) today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the “HSR Act”) in connection with Roche’s pending acquisition of Spark. (Source: Roche Investor Update)
Source: Roche Investor Update - April 3, 2019 Category: Pharmaceuticals Source Type: news

Invitation to Roche's live audio webcast on data presented at AAN 2019 - 13 May 2019
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 13 May 2019, highlighting Roche data presented at the American Academy of Neurology (AAN) Annual Meeting (4-10 May 2019) in Philadelphia, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - April 1, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
Roche will today present the initial results from a Phase Ib study evaluating the efficacy and safety for the combination of ipatasertib, Tecentriq ® (atezolizumab) and chemotherapy (paclitaxel or nab-paclitaxel (Abraxane® [paclitaxel albumin-bound particles for injectable suspension]) as a first-line treatment option for people with advanced triple-negative breast cancer (TNBC). (Source: Roche Investor Update)
Source: Roche Investor Update - April 1, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 19, 2019 Category: Pharmaceuticals Source Type: news

Invitation to Roche's First Quarter Sales 2019 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2019 prior to the opening of the Swiss Stock Exchange on Wednesday, April 17th, 2019 (Source: Roche Investor Update)
Source: Roche Investor Update - March 18, 2019 Category: Pharmaceuticals Source Type: news

Roche to present results of the largest safety study of its kind with Tecentriq (atezolizumab) in patients with metastatic bladder cancer
Roche today announced first results from SAUL, a Phase IIIb study evaluating the safety of Tecentriq ® in approximately 1000 patients with locally advanced or metastatic urothelial carcinoma (mUC) including several clinically relevant populations reflective of real-world clinical practice (patients with renal impairment, poor performance status (ECOG PS 2), treated asymptomatic CNS metastases, sta ble controlled autoimmune disease). (Source: Roche Investor Update)
Source: Roche Investor Update - March 18, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s MabThera (rituximab) for a rare autoimmune disease
Roche today announced that the European Commission has approved MabThera ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterised by progressive painful blistering of the skin and/or mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - March 15, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII deficiency, FVIII (Source: Roche Investor Update)
Source: Roche Investor Update - March 14, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
Roche today announced US Food and Drug Administration approval of the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying triple-negative breast cancer (TNBC) patients eligible for treatment with the Roche cancer immunotherapy Tecentriq ®(atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]). (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test. (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 8, 2019 Category: Pharmaceuticals Source Type: news

Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc. (NASDAQ: ONCE) at a price of US$ 114.50 per share. (Source: Roche Investor Update)
Source: Roche Investor Update - March 7, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - March 7, 2019 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s supplemental new drug application for Xofluza (baloxavir marboxil) for the treatment of influenza in people at high risk of complications
Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Xofluza ™ (baloxavir marboxil) as a single-dose, oral treatment for people at high risk of complications from the flu. (Source: Roche Investor Update)
Source: Roche Investor Update - March 6, 2019 Category: Pharmaceuticals Source Type: news

Roche Annual General Meeting 2019
Roche today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). The 840 attending shareholders, representing 86.73% of the total of 160,000,000 shares, approved the Management Report, the Financial Statements and the Consolidated Financial Statements for 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - March 5, 2019 Category: Pharmaceuticals Source Type: news

Save the date: Roche Analyst Event at ASCO 2019 - Monday, 3 June 2019
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group's oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (31 May - 4 June 2019). (Source: Roche Investor Update)
Source: Roche Investor Update - March 4, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta ™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metast atic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - February 28, 2019 Category: Pharmaceuticals Source Type: news

Roche enters into definitive merger agreement to acquire Spark Therapeutics
Roche and Spark Therapeutics, Inc. today announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction. (Source: Roche Investor Update)
Source: Roche Investor Update - February 25, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review to Roche ’s personalised medicine entrectinib
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumours who have either progressed following prior therapies or as an initial therapy when there are no acceptable standard therapies, and for the treatment of people with metastatic, ROS1-positive non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 19, 2019 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s polatuzumab vedotin in previously treated aggressive lymphoma
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). (Source: Roche Investor Update)
Source: Roche Investor Update - February 19, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - February 5, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra ®(emicizumab) for routine prophylaxis of bleeding episodes in adults and children with severe haemophilia A (congenital factor VIII deficiency, FVIII (Source: Roche Investor Update)
Source: Roche Investor Update - February 1, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) . (Source: Roche Investor Update)
Source: Roche Investor Update - February 1, 2019 Category: Pharmaceuticals Source Type: news

Roche reports very strong results in 2018
Group sales increase 7% at constant exchange rates and in Swiss francs (Source: Roche Investor Update)
Source: Roche Investor Update - January 31, 2019 Category: Pharmaceuticals Source Type: news

Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer ’s disease (AD) - other company programmes in AD continue
- Roche today announced the decision to discontinue CREAD I and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with early (prodromal to mild) sporadic Alzheimer ’s disease (AD). The decision was based on the results of a pre-planned interim analysis assessing the safety and efficacy of crenezumab conducted by the Independent Data Monitoring Committee, which indicated that crenezumab was unlikely to meet the primary endpoint of change from baseline in Clin ical Dementia Rating-Sum of Boxes (CDR-SB) Score. No safety signals for crenezumab were obse...
Source: Roche Investor Update - January 30, 2019 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's Full Year Results 2018 Presentation
Roche will publish its Full Year Results for 2018 prior to the opening of the Swiss Stock Exchange on Thursday, 31 January 2019. (Source: Roche Investor Update)
Source: Roche Investor Update - January 23, 2019 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. (Source: Roche Investor Update)
Source: Roche Investor Update - January 17, 2019 Category: Pharmaceuticals Source Type: news

Invitation to Roche's Full Year Results 2018 Presentation
Roche will publish its Full Year Results for 2018 prior to the opening of the Swiss Stock Exchange on Thursday, 31 January 2019. (Source: Roche Investor Update)
Source: Roche Investor Update - January 7, 2019 Category: Pharmaceuticals Source Type: news

Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the Treatment of NTRK Fusion-Positive Solid Tumors
(Source: Roche Investor Update)
Source: Roche Investor Update - December 19, 2018 Category: Pharmaceuticals Source Type: news

Chugai announed satralizumab receives FDA Breakthrough Therapy Designation for NMOSD
(Source: Roche Investor Update)
Source: Roche Investor Update - December 19, 2018 Category: Pharmaceuticals Source Type: news

Chugai ’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD
(Source: Roche Investor Update)
Source: Roche Investor Update - December 19, 2018 Category: Pharmaceuticals Source Type: news

PRIME designation granted by European Medicines Agency for Roche ’s risdiplam for treatment of spinal muscular atrophy (SMA)
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational oral medicine risdiplam (RG7916) for the treatment of people with SMA. (Source: Roche Investor Update)
Source: Roche Investor Update - December 17, 2018 Category: Pharmaceuticals Source Type: news

New member proposed for election to Roche Board of Directors
Roche today announced that at its December meeting the Board of Directors (BoD) of Roche Holding Ltd decided on first proposals for approval by the Annual General Meeting (AGM), scheduled for 5 March 2019. (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2018 Category: Pharmaceuticals Source Type: news

Changes to the Roche Corporate Executive Committee
Roche today announced that Daniel O ’Day, CEO Roche Pharmaceuticals and member of the Corporate Executive Committee, will be stepping down from his role as of 31 December 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2018 Category: Pharmaceuticals Source Type: news

Chugai Receives Orphan Drug Designation for TECENTRIQ ® in Small cell Lung Cancer and for Entrectinib in NTRK Fusion-positive Solid Tumors
(Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2018 Category: Pharmaceuticals Source Type: news

Chugai Presents Interim Analysis Data of Phase I/II Study of SKY59, anti-C5 antibody in PNH at ASH
(Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
Roche today announced data from the primary analysis of the phase III HAVEN 2 study evaluating Hemlibra ® (emicizumab) prophylaxis in children younger than 12 years of age with haemophilia A with factor VIII inhibitors, including longer follow-up for once-weekly dosing and new data for less frequent dosing schedules (every two weeks or every four weeks). (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche ’s live audio webcast at the 2018 American Society of Hematology’s 60 th Annual Meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 4 December 2018, highlighting the results from important clinical studies which Roche will present at the upcoming American Society of Hematology (ASH) 60th Annual meeting in San Diego, California, from 1-5th December. (Source: Roche Investor Update)
Source: Roche Investor Update - November 27, 2018 Category: Pharmaceuticals Source Type: news

FDA approves the ACTPen for Roche ’s Actemra, a single-dose, prefilled autoinjector for the treatment of rheumatoid arthritis, giant cell arteritis and two forms of juvenile arthritis
Roche announced today that the US Food and Drug Administration (FDA) has approved ACTPen ™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra®(tocilizumab) as an additional formulation for adult patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), and for adul t patients with giant cell arteritis (GCA). (Source: Roche Investor Update)
Source: Roche Investor Update - November 26, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Venclexta ® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or low dose cytarabine (LDAC), for the treatment of people with newly-diagnosed acute myeloid leukaemia (AML), who are age 75 years or older, or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - November 21, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast can cer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing. (Source: Roche Investor Update)
Source: Roche Investor Update - November 13, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
Roche today announced that new data for its approved and investigational medicines across a range of blood diseases, and including several first-in-class medicines, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting from 1-4 December, 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche's live audio webcast at the 2018 American Society of Hematology's 60th Annual Meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 4 December 2018, highlighting the results from important clinical studies which Roche will present at the upcoming American Society of Hematology (ASH) 60th Annual meeting in San Diego, California, from 1-5th December. (Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news